Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-month effects on coronary flow reserve and angiogenic cell mobilisation

Soon Jun Hong; Seung Cheol Choi; Jae Sang Kim; Wan Joo Shim; Seong Mi Park; Chul Min Ahn; Jae Hyung Park; Yong Hyun Kim; Do-Sun Lim
May 2010
Heart;May2010, Vol. 96 Issue 10, p756
Academic Journal
Objective To compare the effects of atorvastatin 10 mg versus 40 mg in circulating angiogenic cell mobilisations and in restoring coronary flow reserve (CFR) during the 8-month follow-up in patients with a first acute myocardial infarction (AMI). Design CFR was measured using an intracoronary Doppler wire in 102 patients with AMI at baseline and at 8 months. Changes in the absolute number of circulating angiogenic cells were measured at baseline, 1 day, 5 days and at 8 months. Stented patients were randomly assigned to either low-dose atorvastatin 10 mg (ATOR10, n=52) or moderate-dose atorvastatin 40 mg (ATOR40, n=50). Setting University Hospital. Results CFR increased significantly in both groups during the 8-month follow-up. The 8-month increases from baseline in CFR were significantly greater in the ATOR40 group than in the ATOR10 group (0.99±0.69 vs 0.55±0.47, p=0.017, respectively). The serial increases in the absolute number of CD34+ and CXCR4+ cells were significantly greater in the ATOR40 group, especially at 24 h after the procedure (two-way repeated-measures analysis of variance: p=0.046 and p=0.022, respectively). Decreases from baseline for interleukin 6 (-2.94±3.31 vs -1.52±2.82 pg/ml), tumour necrosis factor a (-1.31±2.96 vs -0.01±1.29 pg/ml), soluble intercellular adhesion molecule-1 (-71±95 vs 37±83 ng/ml) and soluble vascular cell adhesion molecule-1 (-51±364 vs 190±204 ng/ml) were significantly greater in the ATOR40 group. Conclusions The recovery of microvascular integrity after acute ischaemic injury in the ATOR40 group was expedited by greater circulating angiogenic cell mobilisations such as CD34+ and CXCR4+ cells, together with greater decreases in inflammatory cytokines and low-density lipoprotein-cholesterol concentrations. Registration number http://ClinicalTrials.gov number, NCT00536887.


Related Articles

  • Heart function and cytokine expression is similar in mice and rats after myocardial infarction but differences occur in TNFα expression. Deten, Alexander; Zimmer, Heinz-Gerd // Pflugers Archiv European Journal of Physiology;Nov2002, Vol. 445 Issue 2, p289 

    Large myocardial infarction (MI) causes substantial cardiac remodeling and often leads to heart failure. The genetically engineered mouse is believed to provide a powerful tool for investigating the underlying pathophysiological mechanisms and for developing new therapeutic strategies. The...

  • p55 Tumour necrosis factor receptor in bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein receptor knock-out mice. Xanthoulea, Sofia; Gijbels, Marion J. J.; Van der Made, Ingeborg; Mujčić, Hilda; Thelen, Melanie; Vergouwe, Monique N.; Ambagts, Matheus H. C.; Hofker, Marten H.; De Winther, Menno P. J. // Cardiovascular Research;Nov2008, Vol. 80 Issue 2, p309 

    Aims: Tumour necrosis factor (TNF) is a pivotal pro-inflammatory cytokine with a clear pathogenic role in many chronic inflammatory diseases, and p55 TNF receptor (TNFR) mediates the majority of TNF responses. The aim of the current study was to investigate the role of p55 TNFR expression in...

  • Do elevated lipids call for more than statins? Guthrie, Robert M. // Cortlandt Forum;Jan2008, Vol. 21 Issue 1, p26 

    The article focuses on the concept of clinicians to consider adding another cholesterol-reducing agent to statins to lower the low density lipoproteins (LDL) of patients with acute coronary syndrome and to prevent cardiovascular events. But researchers have stressed that the benefits of such...

  • LDL-lowering Independent Effects of Early Pre-treatment with High-dose Statins in Patients Undergoing Percutaneous Coronary Interventions. Nusca, Annunziata; Melfi, Rosetta; Patti, Giuseppe; Di Sciascio, Germano // European Journal of Cardiovascular Medicine;Sep2011, Issue 3, p13 

    Statins exert beneficial effects on the endothelium, inflammation and the coagulation cascade that are independent of cholesterol lowering. The main mechanism underlying these effects is inhibition of isoprenoid synthesis, modulating the inflammatory cascade and the endothelial activation...

  • Intensive statin therapy reduces cardiovascular events.  // Australian Journal of Pharmacy;Mar2011, Vol. 92 Issue 1090, p76 

    The article offers information on the two studies that differentiate intensive statin regimens with placebo and low dose statin therapy on major cardiovascular events. It highlights the significance of low-density lipoprotein (LDL) as triggering factor for coronary heart disease. It notes that...

  • "Bad" LDL Cholesterol Still Trumps "Good" HDL Cholesterol. Voora, Deepak // DukeMedicine HealthNews;Aug2012, Vol. 18 Issue 8, p1 

    The article focuses on the importance of bad low-density lipoprotein (LDL) cholesterol against the good high-density lipoprotein cholesterol. It notes that while LDL levels can be lowered through exercise and diet, people must take a statin or other cholesterol-lowering medication to achieve the...

  • WHY SOME STATINS WORK BETTER.  // Time International (South Pacific Edition);9/13/2004, Issue 36, p67 

    The article presents information on the disappointing results of the statin drug Zocor. A study shows that the results of the high doses of Zocor on patients are not better than that of low-dose in terms of heart-attack risk, despite having low level of Low Density Lipoproteins (LDL). That is...

  • Statins and Dyslipidemia: Should we be Looking Beyond LDL?  // Primary Care Reports;Jun2012 Clinical Briefs, p1 

    The article reports a study revealing that non-high-density lipoprotein cholesterol (non-HDL-C) was greatly associated with increased risk of cardiovascular events than low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB), emphasizing non-HDL-C reduction in dyslipidemia patients.

  • LDL Hypothesis Alive and Well; Other Biomarkers also Valuable. Morrison, Trista // BioWorld Today;11/11/2008, Vol. 19 Issue 220, p1 

    The article discusses the highlights of studies on reduction of low density lipoproteins (LDL) cholesterol, presented at the American Heart Association's 2008 Scientific Sessions. Crestor resulted in a median 50 percent reduction in (LDL) cholesterol levels and a reduction in major...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics